Task C10: Chemical Synthesis and Process Optimization of an anti-viral for enteroviruses and coronaviruses

任务C10：肠道病毒和冠状病毒抗病毒药物的化学合成和工艺优化

• 批准号: 10263620
• 负责人: GREG MARTIN
• 金额: $ 28.14万
• 依托单位: ALBANY MOLECULAR RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-31 至 2021-05-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10263620
• 关键词: 2019-nCoV; Antiviral Agents; C10; COVID-19; Chemistry; Communicable Diseases; Coronavirus; Development; Development Plans; Drug Kinetics; Enterovirus; Evaluation; In Vitro; Interventional Agent Development; Lead; Microbiology; Safety; Services; Support Contracts; Therapeutic; Toxicology; Toxin; chemical synthesis; in vivo; novel coronavirus; pathogen; pre-clinical; process optimization; product development; programs; therapeutic development

The Non-clinical Services for Development of Interventional Agents for Infectious Diseases program provides services to facilitate preclinical product development of promising therapeutics for infectious disease-causing pathogens and/or toxins. Services include: preclinical product development planning and evaluation; lead identification and development; chemistry and GMP manufacturing; in vitro and in vivo preclinical microbiological, safety, toxicology and pharmacokinetics.

传染病干预药物开发非临床服务项目提供服务，以促进有前景的传染病病原体和/或毒素治疗药物的临床前产品开发。服务包括：临床前产品开发计划和评价;先导化合物鉴定和开发;化学和GMP生产;体外和体内临床前微生物、安全性、毒理学和药代动力学。